Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.

Abstract

BACKGROUND Patients with severe asthma can have eosinophilic inflammation and/or allergen sensitization. Benralizumab is an anti-eosinophilic monoclonal antibody being developed for patients with severe, uncontrolled asthma with eosinophilic inflammation. OBJECTIVE To investigate the efficacy of benralizumab by atopic status and serum immunoglobulin E… (More)
DOI: 10.1016/j.anai.2018.01.030

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics